Preparation of monoclonal antibodies against mouse alpha-fetoprotein and preliminary study on their application

原发性肝癌是我国高发的恶性肿瘤之一，每年新发和死亡患者均占全球总数的一半以上。根据全国肿瘤登记中心最新公布的2015年《肿瘤登记年报》数据，我国肝癌新增病例为46.61万，占所有恶性肿瘤的第4位（10.86%），而死亡病例为42.21万，占所有癌症死亡的第3位（15.00%），仅次于肺癌和胃癌。尽管近年来肝癌的诊断和治疗有了一定的进展，其预后仍然不理想，五年生存率极低。究其原因，大部分肝癌患者往往在疾病的晚期才被诊断出来，有些甚至发生了远端转移，因而错过了最佳治疗时机；此外，目前几乎没有针对中晚期肝癌有效的治疗手段。在这种情况下，迫切需要开发肝癌早期诊断试剂及新型靶向药物，提高治疗效率。 甲...Liver cancer is one of the most common cancers, more than half new cases and deaths occur in China. According the data from National cancer registry in 2015, liver cancer is the fourth most common cancer with high incidence rate (466.1 per 100,000), and is the third leading cause of cancer death (422.1 per 100,000). Although great advances have been made in diagnosis and treatment of liver cancer ...学位：理学硕士院系专业：生命科学学院_水生生物学学号：2162013115248

Oncolytic virus and cancer therapy

溶瘤病毒是目前恶性肿瘤治疗领域中较有前景的新型基因治疗药物,其通过选择性杀伤肿瘤细胞和诱导机体产生特异的抗肿瘤免疫两种途径来实现肿瘤靶向治疗的目的,从而达到较好的抗肿瘤效果。现对溶瘤病毒的溶瘤机制、临床研究、联合治疗和当前挑战及未来展望等方面进行综述。Oncolytic virus are therapeutically promising anticancer viruses that selectively kill cancer cells and induce host anti-tumor immune responses. This review summarizes recent advances and progress in oncolytic virotherapy, including oncolytic mechanism, clinical study, combined therapy, challenges and future prospects.厦门市科技计划项目(3502Z20131001

Amplitude analysis of the decays D0 → π+π−π+π− and D0 → π+π−π0π0*

Using e+e− annihilation data corresponding to an integrated luminosity of 2.93 fb−1 taken at the center-of-mass energy √s = 3.773 GeV with the BESIII detector, a joint amplitude analysis is performed on the decays D0 → π+π−π+π− and D0 → π+π−π0π0 (non-η). The fit fractions of individual components are obtained, and large interferences among the dominant components of the decays D0 → a1(1260)π, D0 → π(1300)π, D0 → ρ(770)ρ(770), and D0 → 2(ππ)S are observed in both channels. With the obtained amplitude model, the CP-even fractions of D0 → π+π−π+π− and D0 → π+π−π0π0 (non-η) are determined to be (75.2 ± 1.1stat. ± 1.5syst.) % and (68.9 ± 1.5stat. ± 2.4syst.)%, respectively. The branching fractions of D0 → π+π−π+π− and D0 → π+π−π0π0 (non-η) are measured to be (0.688 ± 0.010stat. ± 0.010syst.)% and (0.951 ± 0.025stat. ± 0.021syst.)%, respectively. The amplitude analysis provides an important model for the binning strategy in measuring the strong phase parameters of D0 → 4π when used to determine the CKM angle γ(φ3) via the B− → DK− decay

Measurement of integrated luminosity of data collected at 3.773 GeV by BESIII from 2021 to 2024

We present a measurement of the integrated luminosity e+e- of collision data collected by the BESIII detector at the BEPCII collider at a center-of-mass energy of Ecm = 3.773 GeV. The integrated luminosities of the datasets taken from December 2021 to June 2022, from November 2022 to June 2023, and from October 2023 to February 2024 were determined to be 4.995±0.019 fb-1, 8.157±0.031 fb-1, and 4.191±0.016 fb-1, respectively, by analyzing large angle Bhabha scattering events. The uncertainties are dominated by systematic effects, and the statistical uncertainties are negligible. Our results provide essential input for future analyses and precision measurements

Determination of the number of ψ(3686) events taken at BESIII

The number of ψ(3686) events collected by the BESIII detector during the 2021 run period is determined to be (2259.3±11.1)×106 by counting inclusive ψ(3686) hadronic events. The uncertainty is systematic and the statistical uncertainty is negligible. Meanwhile, the numbers of ψ(3686) events collected during the 2009 and 2012 run periods are updated to be (107.7±0.6)×106 and (345.4±2.6)×106, respectively. Both numbers are consistent with the previous measurements within one standard deviation. The total number of ψ(3686) events in the three data samples is (2712.4±14.3)×10^